vaccines
Docs Updates
Study Protocol Study Consent NCT04832932

As of November 25, 2022

Enrolled by August 2022 & Shared Vaccination Experiences: 1430
Postvaccination Surveillance Reports: 655
Reported Breakthrough Infections: 266
Latest fatality: November 22, 2022
Additional cases: 142

Vaccines

RNA

Pfizer-BioNTech, BNT162b2

  • Overview & Safety by CDC
  • What to expect: 18-55
  • What to expect: 55+ 
  • Trials and Approvals
  • Non Replicating Viral Vector

    Johnson/Janssen,  JNJ-78436735 

  • Overview & Safety by CDC
  • What to expect
  • Trials and Approvals
  • Oxford-Astrazeneca,  AZD1222/ChAdOx1 

  • ChemIDPlus
  • What to expect
  • Trials and Approvals
  • Killed/Inactivated virus

    Sinopharm,  BBIBP-CorV 

  • Overview by WHO
  • What to expect
  • Trials and Approvals
  • Sinovac,  CoronaVac 

  • Overview by WHO
  • What to expect
  • Trials and Approvals
  • Bharat Biotech, BBV152 COVAXIN 

  • Overview by WHO
  • What to expect
  • Trials and Approvals
  • Valneva,  VLA2001 

  • Overview by WHO
  • What to expect
  • Trials and Approvals
  • Protein subunit

    Novovax: Nuvaxovid  NVX-CoV2373 

  • Overview by CDC
  • What to expect
  • Trials and Approvals
  • studies aurametrix.com